Delivery of double-stranded DNA thioaptamers into HIV-1 infected cells for antiviral activity

Monique Ferguson, Daniel R. Rojo, Anoma Somasunderam, Varatharasa Thiviyanathan, Bettye D. Ridley, Xianbin Yang, David G. Gorenstein

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Oligonucleotide agents (ODN) are emerging as attractive alternatives to chemical drugs. However, the clinical use of ODNs as therapeutics has been hindered by their susceptibility to degradation by cellular enzymes and their limited ability to penetrate intact cells. We have used various liposome-mediated transfection agents, for the in vitro delivery of DNA thioaptamers into U373-MAGI-CCR5 cells. Our lead thioaptamer, R12-2, targets the RNase H domain of the HIV-1 reverse transcriptase (RT) and inhibits viral infection in U373-MAGI-CCR5 cells. R12-2, a 62-base-pair, double-stranded DNA molecule with a monothio-phosphate modified backbone, was selected through a novel combinatorial selection method. We studied the use of oligofectamine (OF), TFX-20, Transmessenger (TM), and Gene Jammer (GJ) for transfection of the thio-modified DNA aptamers. OF-transfected U373-MAGI-CCR5 cells resulted in 68% inhibition of HIV infection in the treated cells compared to the untreated control. Inhibition was observed in a dose-dependent manner with maximal inhibition of 83%. In this report, we demonstrate that monothioate-modified DNA duplex oligonucleotides can be efficiently delivered into cells by liposome-based transfection agents to inhibit HIV replication.

Original languageEnglish (US)
Pages (from-to)792-797
Number of pages6
JournalBiochemical and Biophysical Research Communications
Volume344
Issue number3
DOIs
StatePublished - Jun 9 2006

Fingerprint

Antiviral Agents
HIV-1
Liposomes
Oligonucleotides
DNA
Nucleotide Aptamers
Ribonuclease H
Transfection
Genes
Phosphates
Cells
Degradation
Molecules
Virus Diseases
Enzymes
Base Pairing
Pharmaceutical Preparations
HIV Infections
HIV
oligofectamine

Keywords

  • HIV
  • Liposomes
  • Oligonucleotide
  • RNase H
  • RT inhibitors
  • Thioaptamer

ASJC Scopus subject areas

  • Biochemistry
  • Biophysics
  • Molecular Biology

Cite this

Delivery of double-stranded DNA thioaptamers into HIV-1 infected cells for antiviral activity. / Ferguson, Monique; Rojo, Daniel R.; Somasunderam, Anoma; Thiviyanathan, Varatharasa; Ridley, Bettye D.; Yang, Xianbin; Gorenstein, David G.

In: Biochemical and Biophysical Research Communications, Vol. 344, No. 3, 09.06.2006, p. 792-797.

Research output: Contribution to journalArticle

Ferguson, Monique ; Rojo, Daniel R. ; Somasunderam, Anoma ; Thiviyanathan, Varatharasa ; Ridley, Bettye D. ; Yang, Xianbin ; Gorenstein, David G. / Delivery of double-stranded DNA thioaptamers into HIV-1 infected cells for antiviral activity. In: Biochemical and Biophysical Research Communications. 2006 ; Vol. 344, No. 3. pp. 792-797.
@article{b4f460e0ccb345838999a0e5a9612d47,
title = "Delivery of double-stranded DNA thioaptamers into HIV-1 infected cells for antiviral activity",
abstract = "Oligonucleotide agents (ODN) are emerging as attractive alternatives to chemical drugs. However, the clinical use of ODNs as therapeutics has been hindered by their susceptibility to degradation by cellular enzymes and their limited ability to penetrate intact cells. We have used various liposome-mediated transfection agents, for the in vitro delivery of DNA thioaptamers into U373-MAGI-CCR5 cells. Our lead thioaptamer, R12-2, targets the RNase H domain of the HIV-1 reverse transcriptase (RT) and inhibits viral infection in U373-MAGI-CCR5 cells. R12-2, a 62-base-pair, double-stranded DNA molecule with a monothio-phosphate modified backbone, was selected through a novel combinatorial selection method. We studied the use of oligofectamine (OF), TFX-20, Transmessenger (TM), and Gene Jammer (GJ) for transfection of the thio-modified DNA aptamers. OF-transfected U373-MAGI-CCR5 cells resulted in 68{\%} inhibition of HIV infection in the treated cells compared to the untreated control. Inhibition was observed in a dose-dependent manner with maximal inhibition of 83{\%}. In this report, we demonstrate that monothioate-modified DNA duplex oligonucleotides can be efficiently delivered into cells by liposome-based transfection agents to inhibit HIV replication.",
keywords = "HIV, Liposomes, Oligonucleotide, RNase H, RT inhibitors, Thioaptamer",
author = "Monique Ferguson and Rojo, {Daniel R.} and Anoma Somasunderam and Varatharasa Thiviyanathan and Ridley, {Bettye D.} and Xianbin Yang and Gorenstein, {David G.}",
year = "2006",
month = "6",
day = "9",
doi = "10.1016/j.bbrc.2006.03.201",
language = "English (US)",
volume = "344",
pages = "792--797",
journal = "Biochemical and Biophysical Research Communications",
issn = "0006-291X",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Delivery of double-stranded DNA thioaptamers into HIV-1 infected cells for antiviral activity

AU - Ferguson, Monique

AU - Rojo, Daniel R.

AU - Somasunderam, Anoma

AU - Thiviyanathan, Varatharasa

AU - Ridley, Bettye D.

AU - Yang, Xianbin

AU - Gorenstein, David G.

PY - 2006/6/9

Y1 - 2006/6/9

N2 - Oligonucleotide agents (ODN) are emerging as attractive alternatives to chemical drugs. However, the clinical use of ODNs as therapeutics has been hindered by their susceptibility to degradation by cellular enzymes and their limited ability to penetrate intact cells. We have used various liposome-mediated transfection agents, for the in vitro delivery of DNA thioaptamers into U373-MAGI-CCR5 cells. Our lead thioaptamer, R12-2, targets the RNase H domain of the HIV-1 reverse transcriptase (RT) and inhibits viral infection in U373-MAGI-CCR5 cells. R12-2, a 62-base-pair, double-stranded DNA molecule with a monothio-phosphate modified backbone, was selected through a novel combinatorial selection method. We studied the use of oligofectamine (OF), TFX-20, Transmessenger (TM), and Gene Jammer (GJ) for transfection of the thio-modified DNA aptamers. OF-transfected U373-MAGI-CCR5 cells resulted in 68% inhibition of HIV infection in the treated cells compared to the untreated control. Inhibition was observed in a dose-dependent manner with maximal inhibition of 83%. In this report, we demonstrate that monothioate-modified DNA duplex oligonucleotides can be efficiently delivered into cells by liposome-based transfection agents to inhibit HIV replication.

AB - Oligonucleotide agents (ODN) are emerging as attractive alternatives to chemical drugs. However, the clinical use of ODNs as therapeutics has been hindered by their susceptibility to degradation by cellular enzymes and their limited ability to penetrate intact cells. We have used various liposome-mediated transfection agents, for the in vitro delivery of DNA thioaptamers into U373-MAGI-CCR5 cells. Our lead thioaptamer, R12-2, targets the RNase H domain of the HIV-1 reverse transcriptase (RT) and inhibits viral infection in U373-MAGI-CCR5 cells. R12-2, a 62-base-pair, double-stranded DNA molecule with a monothio-phosphate modified backbone, was selected through a novel combinatorial selection method. We studied the use of oligofectamine (OF), TFX-20, Transmessenger (TM), and Gene Jammer (GJ) for transfection of the thio-modified DNA aptamers. OF-transfected U373-MAGI-CCR5 cells resulted in 68% inhibition of HIV infection in the treated cells compared to the untreated control. Inhibition was observed in a dose-dependent manner with maximal inhibition of 83%. In this report, we demonstrate that monothioate-modified DNA duplex oligonucleotides can be efficiently delivered into cells by liposome-based transfection agents to inhibit HIV replication.

KW - HIV

KW - Liposomes

KW - Oligonucleotide

KW - RNase H

KW - RT inhibitors

KW - Thioaptamer

UR - http://www.scopus.com/inward/record.url?scp=33646125429&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646125429&partnerID=8YFLogxK

U2 - 10.1016/j.bbrc.2006.03.201

DO - 10.1016/j.bbrc.2006.03.201

M3 - Article

VL - 344

SP - 792

EP - 797

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 3

ER -